

Assessed for eligibility (N=289)
Excluded (N=109)
Not meeting inclusion criteria (N=109)
Refused to participate (N=0)
Other reasons (N=0)
Randomized (N=180)
30 received placebo
23 completed through Week 12
7 discontinued
2 adverse events
2 withdrew consent
1 lost to follow-up
2 unsatisfactory therapeutic effect
30 analyzed
30 received ABT-874 200 mg × 1
28 completed through Week 12
2 discontinued
1 adverse event
0 withdrew consent
0 lost to follow-up
1 unsatisfactory therapeutic effect
30 analyzed
30 received ABT-874 100 mg eow
30 completed through Week 12
0 discontinued
0 adverse events
0 withdrew consent
0 lost to follow-up
0 unsatisfactory therapeutic effect
30 analyzed
30 received ABT-874 200 mg × 4
29 completed through Week 12
1 discontinued
0 adverse events
1 withdrew consent
0 lost to follow-up
0 unsatisfactory therapeutic effect
30 analyzed
30 received ABT-874 200 mg eow
30 completed through Week 12
0 discontinued
0 adverse event
0 withdrew consent
0 lost to follow-up
0 unsatisfactory therapeutic effect
30 analyzed
30 received ABT-874 200 mg weekly
30 completed through Week 12
0 discontinued
0 adverse events
0 withdrew consent
0 lost to follow-up
0 unsatisfactory therapeutic effect
30 analyzed

Fig. 1



Placebo
200 mg x 1
100 mg eow
200 mg x 4
200 mg eow
200 mg weekly
Patients (%)
0
10
20
30
40
50
60
70
80
90
100
Weeks
1
2
4
8
12

Fig. 2




Placebo
200 mg x 1
100 mg eow
200 mg x 4
200 mg eow
200 mg weekly
Mean PASI Improvement (%)
0
10
20
30
40
50
60
70
80
90
100
Weeks
1
2
4
8
12
*

Fig. 3



* 1 of 1 patients in the placebo group who was a PASI 75 responder at Week 12 maintained a PASI 50 response at Week 24 following discontinuation of placebo at Week 12.

Fig. 4A



PASI 75 at Week 24 Following
Therapy Discontinuation at Week 12
% of Patients
100%
80%
60%
40%
20%
0%
7%
23%
60%
60%
73%
83%
PBO
200 mg 1 dose
100 mg eow
200 mg 4 doses
200 mg eow
200 mg weekly
ITT-NRI.

Fig. 4B




PASI 90 at Week 24 Following
Therapy Discontinuation at Week 12
% of Patients
100%
80%
60%
40%
20%
0%
7%
7%
33%
23%
53%
57%
PBO
200 mg
1 dose
100 mg
eow
200 mg
4 doses
200 mg
eow
200 mg
weekly
ITT-NRI.

Fig. 4C



NRI.
*p<0.001 for all active treatment arms vs. placebo.

Fig. 4D